Aimmune Therapeutics, London, United Kingdom, 7 UAMS/Arkansas Children's Hospital, Little Rock, AR. RATIONALE: Current management of peanut allergy is strict allergen avoidance coupled with prompt recognition and symptomatic treatment if exposure occurs. In subjects undergoing peanut desensitization using AR101, an investigational oral biologic with a characterized peanut protein profile, accidental exposures to peanut and other allergens were reported. METHODS: A phase 3 study of experimental peanut desensitization with AR101 recorded discrete accidental food allergen exposures (unintended ingestion of the allergenic food), related adverse events (AEs), and associated rescue medication (subjects aged 4-17-years-old). Eligible subjects reacted to < _100mg peanut protein as determined by a screening double-blind, placebo-controlled food challenge. RESULTS: 66% of subjects reported food allergies other than peanut at enrollment. 19.6% (n577/372) of actively-treated subjects reported 106 accidental exposures while on study: 33 subjects' (8.9%) were attributed to peanut, 50 subjects' (13.4%) to other foods. 33.1% (n540/124) placebotreated subjects reported 56 accidental exposures: 15 subjects' (12.1%) were attributed to peanut and 28 subjects' (22.6%) to other foods. Peanut exposures leading to AEs (active n529, 7.8%; placebo n514, 11.3%) requiring treatment (active n524, 6.5%; placebo n513, 10.5%) were observed in both treatment groups, but were reported less frequently in the AR101 group. Within the actively treated group, peanut exposures leading to AEs or requiring treatment were lower in the maintenance (1.6%) versus up-dosing period (5.1%). CONCLUSIONS: Accidental exposures attributed to peanut were reported less frequently, had fewer associated AEs, and required less rescue medication in the actively treated group compared to the placebo group. Underreporting of exposure possibly occurred if no/mild symptoms were experienced.
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Is Emergency Room Care After Home Use Of An Epinephrine Auto Injector Always Needed? Deanna K. Hamilton, RN; University of North Carolina at Chapel Hill, Chapel Hill, NC. RATIONALE: Emergency room evaluation and observation of patients who have used an epinephrine auto injector to treat an allergic food reaction at home is the standard of care. Requiring patients to go to the ER after epinephrine injection often deters families from administering epinephrine. Withholding or delaying treatment with epinephrine increases the risk of death from anaphylaxis. We hypothesized that this standard could be modified to prompt the early and more frequent use of epinephrine during an allergic reaction without decreasing patient safety. METHODS: A chart review of 47 pediatric subjects who received epinephrine treatment during a food challenge was conducted. All food challenges were initial screening challenges for research study participation. This groups was selected for review because of the high likelihood of allergic reaction. The goal was to see which subjects needed additional medical intervention after the initial dose of epinephrine and therefore would have benefited from ER care. RESULTS: Of the 47 charts reviewed 13(27.6%) of subjects required additional treatment after Epinephrine use to resolve symptoms. Nine (19.1%) needed a second dose of Epinephrine and 4(8.5%) needed an additional dose of oral antihistamines CONCLUSIONS: These findings suggest over 1 out of 4 patients will need additional medical intervention after the initial Epinephrine dose. Therefore the recommendation of seeking ER care after emergency auto injector use is still valid given the high likelihood that additional treatment will be needed. Additionally improved patient education on the importance of early epinephrine use and ER care may be needed. RATIONALE: For individuals with peanut allergy, avoiding illness can at times be difficult due to undetermined amounts of allergens in foods. A portable consumer device for testing peanut levels in foods could aid. Described are independent validation studies to evaluate the performance of such a newly developed portable peanut sensor for foods. METHODS: In one study, 29 different commercially available quality control and reference materials obtained from various accredited providers were tested in replicates of 6 using the device. An additional evaluation was performed using 10 food matrices spiked to concentrations of peanut ranging from 5 ppm to 100 ppm, with the 0 ppm matrices used as negative controls. RESULTS: The first study yielded an average Accuracy of 98.7% (6 1.8% CL) at the device LOD of 10 ppm, and above. The average True Positive Rate (TPR) was 98.9% (62.2% CL). For the second study, Accuracy was 99.2% (6 1.1% CL) and the TPR was 100% for approved samples. The device correctly identified samples spiked to 10 ppm and above that had also been identified with ELISA testing as containing peanut above the LOQ of the assay. CONCLUSIONS: Independent validation of the peanut sensor device indicated that at 10 ppm peanut detection, the device has the potential to aid sensitive individuals in their daily food choices.
